Use the hyperlinks, where available to access additional clinical trial information.
An Open-Label, Randomized, Phase 3 Clinical Trial of REGN2810 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Carcinoma
Eligible patients will be randomised to receive Cemiplimab or the investigator's choice of chemotherapy for up to 96 weeks. The different chemotherapy options for the investigator to choose from include: (1) Antifolate: Pemetrexed, (2) Topoisomerase 1 inhibitor: Topotecan or Irinotecan, (3) Nucleoside analogue: Gemcitabine or (4) Vinca alkaloid: Vinorelbine. Following the treatment phase, patients will enter the follow up period, which will continue until death, completion of the study or withdrawal of the patient.